Gene dosage, among other factors, affects gene expression in tumors (Albertson et al., 2000; Pollack et al., 2002) , and can be measured on a genome-wide basis at high resolution by array comparative genomic hybridization (array CGH) (Pinkel and Albertson, 2005) . Except for visualization implementations (Pollack et al., 2002; Autio et al., 2003) , and calculation of correlations without formal inference (Nigro et al., 2005) , sophisticated techniques for the integration of array CGH with expression array data are limited. A statistical tool for the detection of genes whose expression is affected by gene dosage within a series of samples is currently not available. ACE-it tests whether on a particular chromosomal location the RNA expression ratios are affected by the gene dosage. The relation with gene dosage is tested by ACE-it for each gene on the expression array. For this purpose gene dosage is divided into three categories: loss, normal or gain, defined by means of a user chosen cut-off for smoothed data (Olshen et al., 2004; Jong et al., 2004) . Subsequently, the chromosomal positions are divided into two groups: positions at which the samples have either normal and gain, or normal and loss. The grouping disregards positions at which all the samples fall into one category, have a balanced distribution over the categories, or have no normals. The restriction into these two groups of chromosomal positions is biologically motivated by the assumption that for a given chromosomal location either oncogenes or tumor suppressor genes drive the chromosomal gain or loss (Albertson et al., 2000; Pinkel and Albertson, 2005) . ACE-it allows a user-defined cut-off for contaminating samples within the groupings.
Thus, normalized expression ratios for a particular gene are compared between the two categories within a group. ACE-it assumes that expression increases with increased gene dosage. This assumption leads to the null-hypothesis: (1) the median expression in samples with a gain is equal or smaller than that in samples with normal gene dosage; or, (2) the median expression in samples with a normal is equal or smaller than that in samples with a loss. We use the one-sided Wilcoxon's rank test to test this null-hypothesis, and apply the Benjamini-Hochberg's multiplicity correction to the resulting P-values (Benjamini and Hochberg, 1995) . Genes whose adjusted P-value is smaller than the userdefined rejection level are considered differentially expressed between gene dosage levels. One compounding problem when linking gene dosage and RNA expression is that often the two arrays for expression and CGH are performed on different platforms (Ylstra et al., 2006) . As a consequence, the arrays can have different elements spotted such that amount and chromosomal position of the ratios measured do not overlap. We solved this by imputing segmented ratios for each chromosomal position not covered by the arrayed elements, such that any given position on the chromosome gets assigned the smoothed array CGH value of the closest physical point of measurement. If expression and CGH array are performed on the same platform this feature may be disenabled.
ACE-it has been developed for the statistical software package R (http://www.r-project.org/) and a graphical user interface (GUI) for windows is provided. ACE-it was tested using array expression and array CGH datasets from various institutes and platforms, including a breast tumor series (Pollack et al., 2002) . This yielded several genes whose expression is significantly affected by gene dosage, including HER-2/neu (c-erbB-2) which is amplified in 20-30% of breast cancer cases (Fig. 1) .
